Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Equity Ratio (2023 - 2025)

Historic Equity Ratio for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to 0.94.

  • CG Oncology's Equity Ratio fell 303.54% to 0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.94, marking a year-over-year decrease of 303.54%. This contributed to the annual value of 0.97 for FY2024, which is 25730.72% up from last year.
  • CG Oncology's Equity Ratio amounted to 0.94 in Q3 2025, which was down 303.54% from 0.96 recorded in Q2 2025.
  • CG Oncology's Equity Ratio's 5-year high stood at 0.98 during Q1 2024, with a 5-year trough of 0.62 in Q4 2023.
  • Moreover, its 3-year median value for Equity Ratio was 0.97 (2024), whereas its average is 0.77.
  • Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 25730.72% in 2024, then tumbled by 303.54% in 2025.
  • Quarter analysis of 3 years shows CG Oncology's Equity Ratio stood at 0.62 in 2023, then soared by 257.31% to 0.97 in 2024, then decreased by 3.04% to 0.94 in 2025.
  • Its Equity Ratio was 0.94 in Q3 2025, compared to 0.96 in Q2 2025 and 0.97 in Q1 2025.